1. No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments
- Author
-
Elisa Teyssou, Roland Tubiana, Vincent Calvez, Cathia Soulié, Anne Simon, Marc Wirden, Romain Palich, Sophie Sayon, Anne-Geneviève Marcelin, Mouna Chebbi, Christine Katlama, Basma Abdi, Marc-Antoine Valantin, and Sophie Seang
- Subjects
Microbiology (medical) ,Population ,Integrase inhibitor ,HIV Infections ,HIV Integrase ,medicine.disease_cause ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Drug Resistance, Viral ,medicine ,Humans ,Pharmacology (medical) ,HIV Integrase Inhibitors ,030212 general & internal medicine ,education ,Pharmacology ,0303 health sciences ,Mutation ,education.field_of_study ,biology ,030306 microbiology ,business.industry ,Inhibitor resistance ,RNA ,Virology ,3. Good health ,Integrase ,Infectious Diseases ,HIV-1 ,Hiv 1 integrase ,biology.protein ,Recombinant DNA ,business - Abstract
BackgroundLittle is known about HIV-1 integrase inhibitor resistance in the CNS.ObjectivesThis study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma.MethodsHIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care.ResultsAmong the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85–5.80) and 3.59 (2.16–4.50) log10 copies/mL versus 4.79 (3.56–5.25) and 3.80 (2.68–4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients.ConclusionsThis work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.
- Published
- 2021